Trial
NCT04603937
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Kodiak Sciences Inc
Collaborators
—
Condition
Diabetic Macular Edema
Intervention
KSI-301
Why stopped
Study did not meet primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-22